Interview with Carmen Ferlito, President & CEO, Ferlito
Ferlito Farmaceutici was established in 1937 and has since then grown to become one of the most renowned pharmaceutical pre-wholesalers in Italy. Which specific values of Ferlito do you think…
Assogenerici (National Association of Generic Drugs Industries) is the official representative body of the industry of generic drugs and biosimilars in Italy, at the forefront in providing medicines at affordable prices and high quality for millions of citizens, helping to boost competition and innovation in the pharmaceutical sector. Associated companies both small and medium corporations for a wide range of drugs, by perfusion with Galen to traditional generics to cutting biosimilars, is distributed in pharmacies at public hospitals.
Established in 1993, Assogenerici represents over 50 pharmaceutical companies. The companies represented in Assogenerici provide 10,000 direct jobs in Italy over the important induced, highly specialized. Generic drugs generate over € 400 million of savings per year for the NHS and for patients, helping to ensure patient access to essential drugs releasing at the same time, valuable resources for new and expensive drug therapies.
Assogenerici plays an important advisory role in the Italian health sector. Assogenerici and its members are working with the Italian and European institutions to develop sustainable solutions for pharmaceutical care and to increase the competitive strength of Italy in the world pharmaceutical market.
Passeggiata di Ripetta, 22 – int. 1 – 00186 – Roma
Tel: +39.06.59.60.53.24
Fax: +39.06.54.31.323
E-mail: info@assogenerici.it
Posta Elettronica Certificata: assogenerici@pec.
Web: assogenerici.it
Ferlito Farmaceutici was established in 1937 and has since then grown to become one of the most renowned pharmaceutical pre-wholesalers in Italy. Which specific values of Ferlito do you think…
After 67 years in the pharmaceutical industry, of which 45 at the head of Menarini, what would you say have been your personal keys to success? Most of my life,…
Recordati was created in 1926, and the combined work of three generations turned the small laboratory not only into a local success story but also a broad European Group. Your…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization of the Agency in…
When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the existing portfolio- and the company’s sales have impressively tripled in…
Intermediate distribution plays a crucial role in establishing bridges between industrial production and final delivery to patients- and in Italy, this function is executed with highly contained costs and commercial…
You have led a successful career within the Solvay Group in various European countries. Looking back at all these international assignments, including you current function of regional Director South Europe,…
Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report…
After long experience in the pharmaceutical industry, working in both multinational and local laboratories, you took the reins of the already well-established Italian subsidiary of Ferring a few months ago.…
See our Cookie Privacy Policy Here
